Creating the Next Wave of Multifunctional Antibodies

Our company is advancing the next major wave of antibody technology which we call the "Third Arc." During the "first arc" of antibody therapeutics, drugs were typically designed to engage a single target, often a cytokine or a cell surface protein. The "second arc" advanced the capabilities of antibodies with novel Fc engineering or payloads. Now, the "Third Arc" of biologics leverages the transformational capabilities of multifunctional antibodies that engage multiple targets and multiple cell types.

Third Arc Bio's approach unlocks the powerful biology of immune synapses to address large unmet need in complex disease areas like solid tumors and immunology and inflammation (I&I).